Znaleziono wyników: 3

Liczba wyników na stronie

Wyniki wyszukiwania

Sortuj według:

Ogranicz wyniki do:

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

The role of immune checkpoint inhibitors in prostate cancer

100%

Surdacki G., Szudy-Szczyrek A., Goracy A., Chyl-Surdacka K., Hus M.

Annals of Agricultural and Environmental Medicine

2019

tom 26

nr 1

The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma

86%

Szudy-Szczyrek A., Legiec W., Manko J., Gmyz K., Szczyrek M., Hus M.

Health Problems of Civilization

2015

tom 09

nr 2

Multiple myeloma is a neoplastic disease which is characterised by proliferation of monoclonal plasmocytes in the bone marrow. It is the second most common hematologic cancer and it represents 1% of all cancer deaths. Despite enormous development in multiple myeloma biology and treatment over the last 30 years - it is still incurable disease with a median survival of 50 – 55 months. Currently, one of the most important goals in the treatment of multiple myeloma is to achieve long-term control of the disease, without negative impact on the patient’s quality of life. Thanks to therapeutic regimens based on new immunomodulatory drugs, this aim seems to be achievable. In this paper we present the case of a female patient living with multiple myeloma for 14 years. Initially patient was treated with standard VAD (vincristine, doxorubicin, dexamethasone) chemotherapy regimen. After a nearly complete remission of the disease, autotransplantation of hematopoietic cells was performed. One year after transplantation there was a relapse of the disease. In the treatment of relapse it was decided to use scheme based on lenalidomide and dexamethasone. After 4th cycle of treatment, a complete remission was achieved. So far, the patient received 149 cycles. In the evaluation of minimal residual disease still maintains a state of complete remission maintains. During over 12 years of treatment no complications in grade 3 and 4 of the CTCAE v.4 was observed. Currently the patient is 58 years old, she still receives lenalidomide and leads moderately active life.

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review

72%

Szudy-Szczyrek A., Chocholska S., Bachanek-Mitura O., Czabak O., Mlak R., Szczyrek M., Muzyka-Kasietczuk J., Hus M.

Annals of Agricultural and Environmental Medicine

2022

tom 29

nr 1

Ograniczanie wyników

2 Annals of Agricultural and Environmental Medicine

1 Health Problems of Civilization

3 Hus M.

3 Szudy-Szczyrek A.

2 Szczyrek M.

1 Bachanek-Mitura O.

1 Chocholska S.

1 Chyl-Surdacka K.

1 Czabak O.

1 Gmyz K.

1 Goracy A.

1 Legiec W.

1 Manko J.

1 Mlak R.

1 Muzyka-Kasietczuk J.

1 Surdacki G.

1 2022

1 2019

1 2015

Wyniki wyszukiwania

The role of immune checkpoint inhibitors in prostate cancer

The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review